GlassScriptPhysician profile
Tammy Trabosh
NPI 1952602617
$4,659.94
in general payments reported to CMS, 2019-2025
21 companies · $1,788 in 2025
The $1,788 reported for 2025 was more than what 99% of Pediatrics, Critical Care providers received nationally (typical 2025 total: $80.91).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $433 · 2022: $1,143 · 2023: $1,112 · 2024: $185 · 2025: $1,788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,335 · Travel and Lodging: $749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,334.76 |
| Travel and Lodging | $749.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,328.54 | 2021-2025 | Fintepla, Briviact |
| Livanova USA, INC. | $1,318.69 | 2023-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Jazz Pharmaceuticals INC. | $532.60 | 2022-2025 | |
| Neurelis, INC. | $293.76 | 2021-2023 | Valtoco |
| Sunovion Pharmaceuticals INC. | $198.59 | 2021-2022 | |
| Aquestive Therapeutics, INC. | $198.46 | 2021-2022 | |
| Biocodex, INC. | $138.60 | 2023-2025 | Diacomit |
| Sk Life Science, INC. | $137.58 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $96.61 | 2023 | Aptiom |
| Immedica Pharma US, INC. | $65.21 | 2022-2025 | Ztalmy |
| Supernus Pharmaceuticals, INC. | $61.52 | 2021-2022 | |
| Aprecia Pharmaceuticals, LLC | $46.54 | 2022-2023 | Spritam |
| Biogen, INC. | $44.48 | 2023 | Spinraza |
| Ironshore Pharmaceuticals INC. | $43.75 | 2022-2023 | Jornay Pm |
| Eisai INC. | $33.73 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $27.26 | 2025 | |
| Otter Pharmaceuticals, LLC | $24.82 | 2025 | Sympazan |
| Azurity Pharmaceuticals, INC. | $22.42 | 2022 | |
| Aucta Pharmaceuticals, INC. | $17.38 | 2025 | Motpoly Xr |
| Corium, LLC | $16.29 | 2023 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $13.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Trabosh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.